Monk, BJ, Tan, DSP, Chagul, JDH, et al. Proportions and incidence of locally advanced cervical cancer: a global systematic literature review. Int J Gynecol Cancer 32 (2022), 1531–1539.
Gennigens, C, De Cuypere, M, Hermesse, J, et al. Optimal treatment in locally advanced cervical cancer. Expert Rev Anticancer Ther 21 (2021), 657–671.
Lorusso, D, Xiang, Y, Hasegawa, K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2024 published online Sept 14. https://doi.org/10.1016/S0140-6736(24)01808-7.
Oaknin, A, Gladieff, L, Martinez-Garcia, J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet 403 (2024), 31–43.
Monk, BJ, Colombo, N, Tewari, KS, et al. First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol 41 (2023), 5505–5511.
Tewari, KS, Monk, BJ, Vergote, I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 386 (2022), 544–555.
Lorusso, D, Xiang, Y, Hasegawa, K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 403 (2024), 1341–1350.
US FDA. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III–IVA cervical cancer. 2024, US Food and Drug Administration https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemoradiotherapy-figo-2014-stage-iii-iva-cervical-cancer. (Accessed 12 January 2024)
Macdonald, OK, Chen, J, Dodson, M, et al. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol 32 (2009), 411–416.
Pinto, PJJ, Chen, MJ, Santos Neto, E, et al. Prognostic factors in locally advanced cervical cancer with pelvic lymph node metastasis. Int J Gynecol Cancer 32 (2022), 239–245.
Monk, BJ, Toita, T, Wu, X, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol 24 (2023), 1334–1348.
McCormack, M, Gallardo Rincón, D, Eminowicz, G, et al. A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial. Ann Oncol, 34(suppl 2), 2023, S1276 (abstr).
Lindegaard, JC, Petric, P, Tan, LT, et al. Are we making progress in curing advanced cervical cancer-again?. Int J Gynecol Cancer, 2024 published online July 10. https://doi.org/10.1136/ijgc-2024-005572.
Liu, K, Zhu, Y, Zhu, H, 27P Concurrent chemoradiotherapy and immunotherapy for locally advanced cervical cancer: a cost-effectiveness analysis based on the KEYNOTE-A18 trial. ESMO Open, 9(suppl 5), 2024, 103527 (abstr).
Massobrio, R, Bianco, L, Campigotto, B, et al. New frontiers in locally advanced cervical cancer treatment. J Clin Med, 13, 2024, 4458.
Simms, KT, Keane, A, Nguyen, DTN, et al. Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nat Med 29 (2023), 3050–3058.
